Education
About Us
Working with TipRanks
Follow Us
Smith & Nephew Snats (SNN)
NYSE:SNN
SNN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.65 - $31.72
Previous CloseN/A
Volume262.39K
Average Volume (3M)748.40K
Market Cap
$12.25B
Enterprise Value$13.89B
Total Cash (Recent Filing)$302.00M
Total Debt (Recent Filing)$3.08B
Price to Earnings (P/E)29.8
Beta0.70
Next Earnings
Jul 31, 2025EPS Estimate
0.84Next Dividend Ex-Date
Mar 28, 2025Dividend Yield2.58%
Share Statistics
EPS (TTM)0.94
Shares Outstanding437,205,050
10 Day Avg. Volume675,109
30 Day Avg. Volume748,405
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)N/A
Price to Sales (P/S)2.11
Price to Cash Flow (P/CF)8.20
P/FCF Ratio10.00
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.43
Enterprise Value/Ebitda5.95
Forecast
1Y Price Target
$28.47Price Target Upside1.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Smith & Nephew Snats News
---
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceSNN posted an encouraging Q4 with top line beating expectations as US Recon performance trended in the right direction and SNN saw +23.9% growth in Other Recon with a record quarter of CORI placements.
Product LaunchesSNN's new launches are leveraging higher-growth end markets, including 510(K) clearance for its shorter hip stem CATALYSTEM and its TOTAL ANKLE Patient-Matched Guides.
US Orthopedics GrowthOrthopedics grew with positive US traction in knees/hips, driven by growth in the US positive for hips and knees turning positive.
Bears Say
China Market ChallengesChina remained a headwind to the tune of 280bps on group underlying revenue growth as VBP impacts on Sports Med and reduced distributor inventory purchasing in Recon persisted.
Orthopedics Segment PerformanceOrtho segment ROIC still remains materially below SNN's other segments, while China headwinds continue to persist in multiple areas of the business.
Revenue GuidanceSNN posted a challenged Q as it missed revenue expectations, lowered its 2024 top line and margin guidance, and also lowered its 2025 margin guidance.
---
Ownership Overview
―
Insiders
0.80% Mutual Funds
4.61% Other Institutional Investors
94.46% Public Companies and
Individual Investors
SNN FAQ
What was Smith & Nephew Snats’s price range in the past 12 months?
Smith & Nephew Snats lowest stock price was $23.65 and its highest was $31.72 in the past 12 months.
What is Smith & Nephew Snats’s market cap?
Smith & Nephew Snats’s market cap is $12.25B.
When is Smith & Nephew Snats’s upcoming earnings report date?
Smith & Nephew Snats’s upcoming earnings report date is Jul 31, 2025 which is in 128 days.
How were Smith & Nephew Snats’s earnings last quarter?
Smith & Nephew Snats released its earnings results on Feb 25, 2025. The company reported $0.935 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.015.
Is Smith & Nephew Snats overvalued?
According to Wall Street analysts Smith & Nephew Snats’s price is currently Undervalued.
Does Smith & Nephew Snats pay dividends?
Smith & Nephew Snats pays a Semiannually dividend of $0.446 which represents an annual dividend yield of 2.58%. See more information on Smith & Nephew Snats dividends here
What is Smith & Nephew Snats’s EPS estimate?
Smith & Nephew Snats’s EPS estimate is 0.84.
How many shares outstanding does Smith & Nephew Snats have?
Smith & Nephew Snats has 437,205,050 shares outstanding.
What happened to Smith & Nephew Snats’s price movement after its last earnings report?
Smith & Nephew Snats reported an EPS of $0.935 in its last earnings report, beating expectations of $0.92. Following the earnings report the stock price went up 6.963%.
Which hedge fund is a major shareholder of Smith & Nephew Snats?
Currently, no hedge funds are holding shares in SNN
---
Smith & Nephew Snats Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.47 (1.21% Upside)
$28.47 (1.21% Upside)
Blogger Sentiment
Bullish
SNN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 633.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 6.0%
Last 30 Days ▲ 19.9%
Last 30 Days ▲ 19.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.82%
12-Months-Change
Fundamentals
Return on Equity
7.82%
Trailing 12-Months
Asset Growth
3.67%
Trailing 12-Months
Company Description
Smith & Nephew Snats
Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It offers the following products and services: sports medicine joint repair; arthroscopic enabling technologies; trauma and extremities; other surgical businesses; knee and hip implants, and advanced wound care, wound bioactives, and wound devices. It operates through the United Kingdom, United States of America, and Other geographical segments. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.
---
SNN Company Deck
---
SNN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with strong growth in key areas, successful execution of strategic plans, and innovation leading to significant revenue contributions. While challenges persist in the China market and in managing R&D investments and cost pressures in Orthopedics, the overall outlook remains optimistic with anticipated improvements in 2025.Read More>---
SNN Stock 12 Month Forecast
Average Price Target
$28.47
▲(1.21% Upside)
Technical Analysis
Baxter International
―
Johnson & Johnson
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Best Analysts Covering SNN
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
-1.22%
reiterated a buy rating 30 days ago
Copying Lisa Bedell Clive's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.22% per trade.
---